* Athira Pharma Inc ATHA.OQ reported a quarterly adjusted
loss
of 65 cents per share for the quarter ended in June. The mean
expectation of six analysts for the quarter was for a loss of 64
cents per share.
* Reported revenue was zero; analysts expected zero.
* Athira Pharma Inc's reported EPS for the quarter was a
loss
of 65 cents.
* The mean earnings estimate of analysts had fallen by
about 1.6%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Athira Pharma Inc shares had risen by 27.9% this
quarter and
lost 70.1% so far this year.
* The company reported a quarterly loss of $24.34 million.
* Wall Street's median 12-month price target for Athira
Pharma Inc
is $5.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 15
at 09:03 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.64 -0.65 Missed
Mar. 31 2022 -0.55 -0.56 Missed
Dec. 31 2021 -0.54 -0.45 Beat
Sep. 30 2021 -0.50 -0.42 Beat